A class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) securities between March 15, 2012 and January 9, 2014.
The complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that Aegerion marketed its drugs in violation of the Federal Food Drug and Cosmetic Act. It is alleged that as a result of these violations, the Company exposed itself to heightened regulatory scrutiny by the FDA and other governmental bodies, and that Aegerion’s statements regarding the Company’s business, operations, and prospects were materially false and misleading.
On January 9, 2014 Aegerion Pharmaceuticals announced that it had received a subpoena from the United States Department of Justice, represented by the U.S. Attorney’s Office in Boston, Massachusetts, requesting documents regarding the Company’s marketing and sale of JUXTAPID in the U.S. Following this news, shares of Aegerion fell $7.98 per share, or nearly 11%, to close at $65.77 per share on very heavy trading volume on January 10, 2014.
The Wites & Rogers seeks to uncover additional information about this substantial loss of shareholder value, and potential investor claims against Aegerion.
If you are an investor who purchased Aegerion stock between March 15, 2012 and January 9, 2014 you may have a legal claim against Aegerion and could serve as the lead plaintiff in a class action lawsuit. If you are interested in being the lead plaintiff, or would like to speak with an attorney about your legal rights, contact the attorneys at Wites & Rogers by email at info@witeslaw.com or toll-free at 1 (866) 277-8631.
The complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that Aegerion marketed its drugs in violation of the Federal Food Drug and Cosmetic Act. It is alleged that as a result of these violations, the Company exposed itself to heightened regulatory scrutiny by the FDA and other governmental bodies, and that Aegerion’s statements regarding the Company’s business, operations, and prospects were materially false and misleading.
On January 9, 2014 Aegerion Pharmaceuticals announced that it had received a subpoena from the United States Department of Justice, represented by the U.S. Attorney’s Office in Boston, Massachusetts, requesting documents regarding the Company’s marketing and sale of JUXTAPID in the U.S. Following this news, shares of Aegerion fell $7.98 per share, or nearly 11%, to close at $65.77 per share on very heavy trading volume on January 10, 2014.
The Wites & Rogers seeks to uncover additional information about this substantial loss of shareholder value, and potential investor claims against Aegerion.
If you are an investor who purchased Aegerion stock between March 15, 2012 and January 9, 2014 you may have a legal claim against Aegerion and could serve as the lead plaintiff in a class action lawsuit. If you are interested in being the lead plaintiff, or would like to speak with an attorney about your legal rights, contact the attorneys at Wites & Rogers by email at info@witeslaw.com or toll-free at 1 (866) 277-8631.
